AstraZeneca has unveiled its innovative oral GLP-1 medication, elecoglipron, which stands to transform the treatment ...

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.

Alison Dziarmaga, Vice President and U.S. Breast Cancer Franchise Head at AstraZeneca, ...

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.

AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...

AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu in early-stage HER2-positive breast cancer in both neoadjuvant and adjuvant settings, based on two phase 3 studies. The FDA also ...

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss ...

The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...

Medications used to treat diabetes and obesity are the hottest commodities in healthcare right now. Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have all become blockbuster ...

A new pill developed by the British pharmaceutical firm AstraZeneca appears to help people lose a similar amount of weight as ...

The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

AstraZeneca has some exciting things going on... AstraZeneca currently has three programs targeting diabetes and obesity care. During the ObesityWeek conference earlier this month, management provided ...